Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28147155 | 0.80 | DDB1 (0.51) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL7678953 | 0.78 | DDB1 (0.61) | PDE4APDE4BPDE4CPDE4DFNTA | |
| SCHEMBL29346871 | 0.78 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DFNTA | |
| SCHEMBL31730010 | 0.77 | LMNA (0.48) | ALDH1A1 | |
| SCHEMBL21805277 | 0.77 | POLB (0.45) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL28408881 | 0.76 | HDAC4 (0.42) | HDAC4HDAC2HDAC8 | |
| SCHEMBL11254018 | 0.76 | KCNH2 (0.50) | FNTAFNTBPGGT1BDDB1CRBN | |
| SCHEMBL2312034 | 0.75 | DDB1 (0.53) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL29346862 | 0.74 | KDM1A (0.40) | PDE4APDE4BPDE4CPDE4DFNTA | |
| SCHEMBL31068532 | 0.74 | KDM1A (0.40) | PDE4APDE4BPDE4CPDE4DFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0003253-B1 | HEXAHYDROAZEPINE, PIPERIDINE AND PYRROLIDINE DERIVATIVES AND PROCESSES FOR MAKING AND USING THEM | JOHN WYETH & BROTHER LIMITED (GB) | 1982-12-22 | — | — | EP | claimed |
| US-4197241-A | Hexahydroazepine, piperidine and pyrrolidine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1980-04-08 | — | — | US | claimed |
| EP-0003253-A1 | Hexahydroazepine, piperidine and pyrrolidine derivatives and processes for making and using them | JOHN WYETH & BROTHER LIMITED (GB) | 1979-08-08 | — | — | EP | claimed |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6284755-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| EP-0003253-B1 | HEXAHYDROAZEPINE, PIPERIDINE AND PYRROLIDINE DERIVATIVES AND PROCESSES FOR MAKING AND USING THEM | JOHN WYETH & BROTHER LIMITED (GB) | 1982-12-22 | — | — | EP | disclosed |
| US-4197241-A | Hexahydroazepine, piperidine and pyrrolidine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1980-04-08 | — | — | US | disclosed |
| EP-0003253-A1 | Hexahydroazepine, piperidine and pyrrolidine derivatives and processes for making and using them | JOHN WYETH & BROTHER LIMITED (GB) | 1979-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | FNTA, PKD1, FNTB | PDE4A 3798/4885PDE4B 4075/4885PDE4C 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.